Please tell us about your clinical experience. How many patients with Alzheimer’s or Parkinson’s disease do you see on a yearly basis? Have you had or heard of experiences with the drug being used under Compassionate/Special Access Scheme?

What is the standard of care treatment? What % of the cases are harder to treat?

What treatment options have gained most traction in recent years?

Can you tell us the details about the mechanism of action of targeting sigma-1 and muscarinic receptors? How efficient can this pathway be towards restoring cellular homeostasis and promoting neuroplasticity, how likely is it to halt and/or reverse the course of Alzheimer’s disease?

What can you tell about the potential anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties of blarcamesine? How likely would you be to include 2-73 blarcamesine in your patients’ treatment courses, in case of a future approval? How much of a need is there for this kind of drug in your practice?

Can you draw any parallels from Anavex’s Rett Syndrome results of blarcamesine?

Oral doses up to 50 mg once daily showed improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis in Parkinson’s Disease Dementia. Results were obtained by targeting SIGMAR1 as a genetic biomarker of response to blarcamesine, how much accuracy does this method provide?